The induced pluripotent stem cell (iPSC) industry is a rapidly evolving area. Since the discovery of iPSCs in 2006, there have been a number of important market events that have occurred, including the first ever clinical trial in humans that was initiated in August 2013 to investigate iPSC-derived cell sheets for restoring vision, as well as large funding awards, major initial public offerings (IPOs), critical patent challenges, and more. [Read more…]
Trend rate data is valuable for understanding current industry conditions, as well as for predicting future behavior within the cord blood industry.
In upcoming posts, we will be presenting a range of valuable trend rate data, pulled from diverse sources, including grant funding databases, patent databases, clinical trial databases, and more.
In this post, we will begin with an analysis of scientific publication rate data for cord blood industry, because it is an important way to gauge innovation and progress within the marketplace.
Scientific Publication Rate Analysis
PubMed is a service of the U.S. National Library of Medicine and the National Institutes of Health (NIH) that contains citations from MEDLINE and a diverse collection of other life science journals. The data below was generated using the PubMed database, because it is the largest, most comprehensive, and most up-to-date global meta-database available for scientific publications.
It is also the most versatile tool for screening by multiple criteria. [Read more…]
The stem cells found in cord blood are largely hematopoietic stem cells, which can help in the replenishment of a depleted blood supply by providing new, healthy cells. In the case of certain diseases, such as leukemia, anemia, lymphoma, and others where the blood cells and tissues are severely affected, this replenishment is essential.
There are several important properties of cord blood, including that the number of hematopoietic stem cells in cord blood equals, or exceeds, the frequency of hematopoietic stem cells in bone marrow. In addition, cord blood hematopoietic stem cells can produce large colonies in vitro, have different growth factor requirements, and can be expanded in long-term culture.
Also, cord blood stem cells are characterized as multipotent, because they are capable of differentiating into numerous stem cell types, including neurons, hepatic cells, and circulating cell types.
Because Google controls over 70% of online searches, it is an incredible resource for analyzing online search behavior. Recently, the search term “Cord Blood” became one of the 20 most expensive keywords on Google Adwords, an incredible finding given the variety and total volume of searches that occur through Google.
In recent groundbreaking research, Dr. William H. Frey II (Director, Alzheimer’s Research Center) and Dr. Lusine Danielyan announced that they have discovered and patented that therapeutic cells, including adult stem cells, can be delivered to the brain using a noninvasive intranasal delivery method.
This non-invasive intranasal method for bypassing the blood-brain barrier can rapidly delivery and target therapeutic agents to the brain along the olfactory and trigeminal neural pathways while reducing systemic exposure and side effects. The intranasal insulin treatment discovered by Dr. Frey for Alzheimer’s disease has been shown in multiple clinical trials to improve memory in both Alzheimer’s patients and normal adults.